Dyslipidemia in Patients with Chronic and End-Stage Kidney Disease

被引：21
作者：
Omran, Jad [1 ]
Al-Dadah, Ashraf [3 ]
Dellsperger, Kevin C. [2 ,3 ]
机构：
[1] Univ Missouri, Sch Med, Dept Internal Med, Columbia, MO 65212 USA
[2] Univ Missouri, Sch Med, Dept Med Pharmacol & Physiol, Columbia, MO 65212 USA
[3] Univ Missouri, Sch Med, Div Cardiovasc Med, Columbia, MO 65212 USA
来源：
CARDIORENAL MEDICINE | 2013年 / 3卷 / 03期
关键词：
Dyslipidemia; Oxidized low-density lipoprotein; Chronic kidney disease; End-stage renal disease; LOW-DENSITY-LIPOPROTEIN; CORONARY-HEART-DISEASE; EXPANDED CLINICAL-EVALUATION; RENAL-TRANSPLANT RECIPIENTS; TYPE-2; DIABETES-MELLITUS; EXTENDED-RELEASE NIACIN; ESTER TRANSFER PROTEIN; C-REACTIVE PROTEIN; CARDIOVASCULAR-DISEASE; PRIMARY-PREVENTION;
D O I：
10.1159/000351985
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In this review, we discuss the physiology, diagnosis and treatment of dyslipidemia in patients with chronic and end-stage renal disease. The recent important clinical trials in patients with chronic kidney disease and dyslipidemia are reviewed. Because of the lack of evidence in treating lipid abnormalities in this specific patient population, we propose that future studies should focus on the pathophysiological mechanisms and treatment of dyslipidemia in this special patient population. Copyright (C) 2013 S. Karger AG, Basel
引用
收藏
页码：165 / 177
页数：13
相关论文
共 50 条
  • [41] Could Antioxidant Supplementation Delay Progression of Cardiovascular Disease in End-Stage Renal Disease Patients?
    Roumeliotis, Stefanos
    Roumeliotis, Athanasios
    Gorny, Xenia
    Mertens, Peter R.
    CURRENT VASCULAR PHARMACOLOGY, 2021, 19 (01) : 41 - 54
  • [42] Chronic inflammation in end-stage renal disease and dialysis
    Cobo, Gabriela
    Lindholm, Bengt
    Stenvinkel, Peter
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33 : 35 - 40
  • [43] Dyslipidemia in patients with chronic kidney disease
    Matthew R. Hager
    Archana D. Narla
    Lisa R. Tannock
    Reviews in Endocrine and Metabolic Disorders, 2017, 18 : 29 - 40
  • [44] Serum Levels of Omentin in End-Stage Renal Disease Patients
    Alcelik, Aytekin
    Tosun, Mehmet
    Ozlu, Mehmet Fatih
    Eroglu, Mustafa
    Aktas, Gulali
    Kemahli, Eray
    Savli, Haluk
    Yazici, Mehmet
    KIDNEY & BLOOD PRESSURE RESEARCH, 2012, 35 (06) : 511 - 516
  • [45] Safety and Efficacy of Statins in Patients With End-Stage Renal Disease
    Nemerovski, Carrie W.
    Lekura, Jona
    Cefaretti, Michelle
    Mehta, Pooja T.
    Moore, Carol L.
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (10) : 1321 - 1329
  • [46] Treatment of ischemic heart disease in end-stage kidney disease patients on renal replacement therapy
    Semenova, Yu V.
    Mironkov, B. L.
    Poz, Ya L.
    VESTNIK TRANSPLANTOLOGII I ISKUSSTVENNYH ORGANOV, 2024, 26 (01): : 26 - 35
  • [47] Dyslipidemia and progression of cardiovascular calcification (CVC) in patients with end-stage renal disease (ESRD)
    Qunibi, WY
    KIDNEY INTERNATIONAL, 2005, 67 : S43 - S50
  • [48] Childhood Albuminuria and Chronic Kidney Disease is Associated with Mortality and End-Stage Renal Disease
    Lin, Ching-Yuang
    Huang, Shiuh-Ming
    PEDIATRICS AND NEONATOLOGY, 2016, 57 (04) : 280 - 287
  • [49] Regadenoson use in chronic kidney disease and end-stage renal disease: A focused review
    Aviral Vij
    Yasmeen Golzar
    Rami Doukky
    Journal of Nuclear Cardiology, 2018, 25 : 137 - 149
  • [50] Regadenoson use in chronic kidney disease and end-stage renal disease: A focused review
    Vij, Aviral
    Golzar, Yasmeen
    Doukky, Rami
    JOURNAL OF NUCLEAR CARDIOLOGY, 2018, 25 (01) : 137 - 149
12345